title: [Specificities of diabetes in acute coronary syndromes].
abstract: Contrary to the decline in the prevalence of several risk factors such as hypertension, hypercholesterolemia and smoking, diabetes is an expanding health burden in the western world. Because of the proatherosclerotic, proinflammatory, and prothrombotic states associated with diabetes, diabetic patients with acute coronary syndromes (ACS) are at high risk of subsequent cardiovascular events. However, they derive greater benefit from aggressive platelet inhibition and an early invasive strategy than non-diabetic individuals. Despite the documented efficacy, diabetic patients with ACS receive evidence-based treatments less frequently than non-diabetic individuals.
authors: Service de médecine interne générale, Département des specialités de médecine, HUG, 1211 Genève 14. Sebastian.Carballo@hcuge.ch
authors: S
authors: S
authors: Carballo
authors: D
authors: D
authors: Carballo
authors: P F
authors: PF
authors: Keller
authors: M
authors: M
authors: Roffi
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D000465:Algorithms; D017130:Angioplasty; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000077144:Clopidogrel; D048909:Diabetes Complications / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D000068799:Prasugrel Hydrochloride; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods; D015607:Stents; D013876:Thiophenes / Q000627:therapeutic use; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D007004:Hypoglycemic Agents; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D013876:Thiophenes; D006493:Heparin; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine